Fortamet

Fortamet is a brand-name formulation of metformin hydrochloride extended-release tablets used to improve glycemic control in adults and in children 10 years and older with type 2 diabetes, as an adjunct to diet and exercise. It is not indicated for type 1 diabetes or for treatment of diabetic ketoacidosis. Fortamet works by reducing hepatic glucose production and by improving insulin sensitivity and peripheral glucose uptake; it does not increase insulin secretion.

Fortamet is an extended-release preparation intended for oral administration, typically taken once daily with the evening meal to improve tolerability and to minimize gastrointestinal side effects associated with metformin. The dose is individualized and often titrated to balance efficacy with tolerability.

Contraindications include impaired renal function, metabolic or lactic acidosis, hypersensitivity to metformin, and conditions that predispose to hypoxia or dehydration (such as acute illness with dehydration). Cautions emphasize monitoring kidney function, avoiding or adjusting use with conditions that can worsen renal function or cause dehydration, and being aware of the rare risk of lactic acidosis, especially in patients with kidney or liver impairment, excessive alcohol use, or acute heart failure. Fortamet may require temporary discontinuation around radiographic contrast studies and reinitiation only after renal function has been reassessed.

Common adverse effects are gastrointestinal, including diarrhea, nausea, vomiting, and abdominal discomfort, which are often transient. Less common but serious adverse effects include lactic acidosis, a rare medical emergency.

Fortamet is primarily eliminated by the kidneys, so dose adjustments or discontinuation may be necessary in renal impairment. It should be used under medical supervision, with information reviewed regarding kidney function, other medications, and any changing health conditions.